Article Details

AstraZeneca, Sanofi post RSV data ahead of 2022 approval filings

Retrieved on: 2021-06-28 11:48:45

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, Sanofi post RSV data ahead of 2022 approval filings. View article details on HISWAI: https://www.fiercebiotech.com/biotech/astrazeneca-sanofi-post-rsv-data-ahead-2022-approval-filings

Excerpt

AstraZeneca and Sanofi's respiratory syncytial virus (RSV) drug candidate nirsevimab has performed similarly to the incumbent product Synagis in a ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up